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Abstract: Crosstalk between innate and adaptive pathways is a critical component to developing
an effective, lasting immune response. Among natural effector cells, innate-like γδ T cells promote
immunity by facilitating communication between the two compartments and exerting cytotoxic effector
functions. Dysregulation of γδ T cell populations is a byproduct of primary human immunodeficiency
virus (HIV) infection. This is most pronounced in the depletion and loss of function within cells
expressing a Vγ9Vδ2 TCR (Vδ2 cells). Whether or not prolonged viral suppression mediated
by antiretroviral therapy (ART) can reverse these effects has yet to be determined. In this study,
we present evidence of similar Vδ2 cell functional responses within a cohort of people living with
HIV (PLWH) that has been stably suppressed for >1 year and uninfected donors. Through the use
of aminobisphosphonate drugs, we were able to generate a comprehensive comparison between
ex vivo and expanded Vδ2 cells within each group. Both groups had largely similar compositions of
memory and effector phenotypes, post-expansion TCR repertoire diversity, and cytotoxic capabilities.
Our findings support the notion that ART promotes the recovery of Vδ2 polyfunctionality and provides
insight for strategies aiming to reconstitute the full immune response after infection with HIV.
Keywords: gammadelta T cells; HIV; antiretroviral therapy; cytotoxicity; TCR
1. Introduction
In contrast to conventional αβ T lymphocytes, γδ T cells are distinguished by the expression of a
T cell receptor (TCR) comprised of heterodimeric γ and δ chains as well as recognition of non-peptide
antigens outside of classical major histocompatibility complex (MHC) presentation [1,2]. A subset
expressing the Vγ9Vδ2 TCR, herein referred to as Vδ2 cells, comprise up to 15% of circulating CD3+
lymphocytes within the peripheral blood of healthy individuals. Vδ2 cells recognize low molecular
weight phosphorylated intermediates of isoprenoid biosynthesis, or phosphoantigens (P-Ag), such as
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isopentyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) [3,4].
Treatment with aminobisphosphonate drugs (N-BPs), such as pamidronate (PAM) or zoledronate (ZOL),
results in the accumulation of IPP and subsequent induction of Vδ2 cell activation [5,6]. Activated Vδ2
cells exert potent cytotoxic capabilities and promote a strong TH1 response to a number of diverse
pathogens and tumor types [7–11]. Cytotoxic effector subsets are distinguished by early expression of
the natural killer cell marker CD56 [12]. Additionally FcγRIII (CD16) expressing Vδ2 cells possess
anti-HIV properties [13], and may play a role in controlling the frequency of latently infected cells [14].
These attributes make Vδ2 cells an attractive therapeutic candidate for innovative strategies targeting
persistent HIV infection [14,15] as well as both solid and hematological malignancies [16]. Clinical trials
of γδ T cell therapies for cancer treatment were generally well tolerated but demonstrated variable
efficacy, most likely due to interpersonal differences in Vδ2 cell population frequencies. The clinical
significance of these differences remains unclear [17,18].
Characterizing the phenotypic differences of Vδ2 cells may provide insights beneficial to adoptive
transfer strategies or targeted therapies. We (P.L.R. and D.J.P) have previously identified four
phenotypically distinct Vδ2 cell populations that vary in frequency between healthy donors [19].
These populations are defined as CD28+CD27+CD16- (γδ(28+)), CD28-CD27+CD16- (γδ(28−)),
CD28-CD27-CD16- (γδ(16−)), and CD28-CD27-CD16+ (γδ(16+)) with γδ(28+) and γδ(16+) being the
immunodominant Vδ2 cell proliferative and cytotoxic responses respectively. Further investigation
of these populations in the context of individual diseases is still needed. Specifically, primary HIV
infection directly causes dysregulation of the natural frequencies, polyfunctionality, and TCR repertoire
of γδ T cells [20]. Whether or not prolonged antiretroviral therapy (ART) is capable of restoring these
properties has yet to be resolved. The number of circulating Vδ2 cells as well as cytotoxic function
and cytokine production remain dampened within the first six months of ART regardless of early
intervention [21]. However, a previous study conducted by our group showed that after one year of
suppressive ART, Vδ2 cells were capable of killing latently infected CD4 T cells despite continued
depression of overall frequencies [22]. Additionally, our understanding of the effects of ART on the Vδ2
TCR repertoire remains limited. Individuals on prolonged ART show only partial recovery highlighted
by an increase in TCR diversity but sustained unresponsiveness to P-Ag [23]. We hypothesized
that despite continued depletion of Vδ2 cells in ART-treated individuals, the phenotypic profiles,
TCR repertoire, and cytotoxic capabilities are comparable to those observed in uninfected individuals.
We conducted comprehensive comparisons of Vδ2 cells phenotype and function between donors from
these two groups. Our study shows that, overall, these Vδ2 cell characteristics in PLWH on suppressive
ART for >1 year are largely similar to uninfected donors.
2. Materials and Methods
2.1. Cells and Cell Lines
Characteristics of the HIV participants included in this study have been previously reported [14,22].
All PLWH were on stable ART with plasma HIV-1 RNA < 50 copies/mL for >1 year before enrollment.
All participants provided written informed consent and studies were approved by the University of
North Carolina’s Institutional Review Board (IRB). Buffy coats from uninfected donors were obtained
from the New York Blood Center (Long Island City, NY, USA) without any identifiers. Daudi human
Burkitt’s lymphoma cell line was obtained from the American type culture collection (ATCC).
2.2. Vδ2 Cell Expansion
PBMCs from ART-suppressed PLWH or uninfected donors were thawed, counted, and rested
overnight. An aliquot was expanded, and the rest was used for phenotypic analysis by flow cytometry.
Five million PBMCs were cultured in media supplemented with 10% FBS and 2.5 µg/mL of PAM
(Sigma-Aldrich, St. Louis, MO, USA) and 100 U/mL of IL-2 (Peprotech, Rocky Hill, CT, USA) for
7 days. Media containing 100 U/mL IL-2 was refreshed at day 3. After seven days of expansion,
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cells were harvested, counted, and resuspended in staining buffer (i.e., 2% FBS in PBS) to perform flow
cytometry assays. Both baseline and expanded cells were stained using the same three monoclonal
antibody panels.
2.3. Vδ2 Cell Phenotypic Analysis
PBMCs were stained using combinations of monoclonal antibodies in three different panels.
For the baseline phenotypic analysis, approximately 40 million PBMCs were enriched for γδ T cells
using a commercially available kit (StemCell Technologies). After expansion, cells were washed
and stained using the same panels for the baseline analysis. The following monoclonal antibodies
(mAbs) were used: CD27 (clone M-T271), CD3 (clone SK7), CD28 (clone CD28.2), CD16 (clone 3G8),
CD69 (clone FN50), HLA-DR (clone L243), Vδ2 (clone M-T271), CD56 (clone HCD56), and PD-1 (clone
EH12.2H7) (all from Biolegend, San Diego, CA, USA except CD3 from BD Biosciences, San Jose,
CA, USA). Cells were incubated in staining buffer with appropriate mAbs for 20 min on ice in the
dark, washed, and fixed in 2% paraformaldehyde (PFA) solution. In some experiments, total PBMCs
and γδ T cell enriched PBMCs were compared in parallel to determine the potential for bias from
the enrichment procedure in our baseline populations. This included an intracellular staining for the
proliferative marker Ki-67 (clone Ki-67). Cells were fixed and permeabilized using Cytofix/Cytoperm
solution (BD Biosciences, San Diego) after extracellular staining. The permeabilized cells were then
washed, incubated in staining buffer with the Ki-67 mAb on ice in the dark, then washed again to
remove any unbound protein. Stained cells were acquired on the Attune NxT (Life Technologies,
Carlsbad, CA, USA) and analyzed using FlowJo v10.1.
2.4. Cytokine Production Analysis
Cytokine production was measured using a previously reported method [24]. Supernatant from
PBMC cultures incubated with 2.5 µg/mL PAM and 100 U/mL IL-2 for seven days were analyzed by
ELISA (Advanced Bioscience Laboratories, Rockville, MD). After the expansion, supernatants from the
7-day expansion were harvested and stored at −80 ◦C until further cytokine ELISA measurement was
performed. IFN-γ, TNF-α, and Granzyme (Grz) B were measured both in cultures from PLWH and
uninfected donors, following the manufacturer’s instructions.
2.5. Degranulation and Cytotoxicity
PBMCs derived from PLWH or uninfected donors, were incubated with PAM and IL-2 for 7 days
and Vδ2 cells were FACS-sorted using a previously reported strategy [25]. Purity of the isolated
populations was >99.9%. Sorted cells were rested overnight in the presence of 30 U/mL IL-2 and
then CD107a (Lamp1) antibody was added to the culture in the presence of Brefeldin A (Biolegend).
Daudi Burkitt’s lymphoma cells lack MHC expression and are highly susceptible to Vδ2 cell-mediated
killing [26]. Daudi cells were cultured alone or added to the culture at a 1:1 (target:effector) ratio for
4 h. Cells were washed and stained for surface markers CD3 and Vδ2 for 20 min on ice. After fixation
and permeabilization (BD biosciences) cells were stained for intracellular markers GrzB and perforin
for 30 min. To analyze Daudi cell killing, the cells were incubated for 15 min with viability dye 7-AAD
(BD Biosciences) prior to the flow cytometry analysis on the Attune NxT (Life Technologies, Carlsbad,
CA, USA) and analyzed using FlowJo v10.1.
2.6. Immune Repertoire Sequencing Assays
One million basal and expanded PBMC from PLWH and uninfected individuals were pelleted
and stored at −80 ◦C. Total RNA was extracted using the Qiagen total RNA isolation mini kit (Qiagen)
and concentration and purity analyzed using the Nanodrop spectrophotometer (Thermofisher).
The genomic libraries were made following Archer VariantPlex Protocol for Illumina (Archer, Cat:
SK0096) which utilizes gene-specific primers for a targeted amplification to identify mutations and
is suited for low DNA input. This protocol was used in conjunction with the corresponding target
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enrichment panel utilizing molecular barcode adapters (MBCs). The kit employs fragmentation by
thermocycler, followed by adding target panel MBCs which tag each DNA molecule with a barcode
and common region, followed by adapter ligation and two steps of PCR amplification. Samples were
then multiplexed together to increase sample diversity before running on a NextSeq 500 (requiring a
spike in of 5% PhiX to increase the library diversity). The samples were identified through both the
molecular tag (added during adapter ligation through the MBC Adapters with the p5/i5 index) and the
barcode/Illumina Index 1 (added during the second PCR cycle with the p7/i7 index) and were analyzed
using Archer Analysis software.
2.7. Statistical Analysis
Data obtained were analyzed using nonparametric methods. Different groups were compared by
Mann–Whitney U test and repeated measures within the same groups were analyzed by Wilcoxon
signed-rank test (paired samples). Fisher’s exact test was used to compare racial distribution
between profiles and Kruskal–Wallis test to compare cell distribution among different profiles. Finally,
Spearman’s rank-order correlation was used to analyze associations between two different continuous
variables. In addition, we used a ranked based version of a mixed effect ANOVA to account for random
subject effects. The thresholds for p-values were corrected for multiple testing. Graphs were created
using GraphPad Prism v.8.4.2 (GraphPad Software, San Diego, CA, USA) and statistical analyses were
performed in the R language and environment for statistical computing (R Development Core Team).
3. Results
3.1. Baseline Characteristics
The study included 23 uninfected donors and 20 PLWH that had been on stable ART, with
plasma viral load <50 copies/mL for at least one year (Table 1). Vδ2 cells are profoundly depleted
in HIV infection [22,27]. In the present study, we found a mean of 0.4% Vδ2 cells within total CD3+
lymphocytes in ART-suppressed PLWH compared to 6.8% in uninfected donors (Supplementary Figure
S1A). In order to more accurately analyze subpopulations within Vδ2 cells of PLWH, we performed a
γδ T cell enrichment prior to baseline phenotypic characterization. The enrichment step did not affect
the phenotype as evidenced by similar expression frequencies of CD27 and CD28 (Supplementary
Figure S1C), activation markers CD69, HLA-DR and proliferation marker Ki67 (Supplementary Figure
S1B) between ex vivo isolated PBMCs and enriched PBMCs. These results indicate a lack of selective
enrichment or depletion of certain populations.
Table 1. Characteristics of PLWH on stable and suppressed ART.
N 20
Age (mean years) 42.3
Sex (% women) 5 (25%)
Race (%)
African American 9 (45%)
Caucasian 10 (50%)
Hispanic 1 (2%)
Treated in the acute phase 5 (25%)
Median Time on ART (years) 6 (1.5–7.1)
Median CD4 nadir (cells/mm3) 392 (299–621)
Median CD4 count (cells/mm3) 776 (597–935)
Median CD8 count (cells/mm3) 742 (470–1010)
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3.2. Comparable Expression of CD16 and CD56 on Vδ2 Cells from Uninfected Donors and PLWH on
Stable ART
We investigated differences in cytotoxic markers CD16 and CD56 expression in Vδ2 cells between
uninfected donors and PLWH, and whether expansion with PAM and IL-2 altered the distribution.
CD16 and CD56 expression on ex vivo Vδ2 cells were similar between uninfected donors and PLWH
(Figure 1A, p = 0.41 for CD16 and p = 0.59 for CD56, Mann–Whitney U-tests). Upon expansion
with PAM and IL-2, CD16 and CD56 expression were upregulated in both uninfected and PLWH
(Figure 1A,B, respectively, p < 0.001, Wilcoxon paired signed-rank tests) showing that Vδ2 cells’ capacity
to upregulate either cytotoxic marker was not impaired in stable durably suppressed PLWH.
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Figure 1. Expression of CD16 and CD56 on Vδ2 cells prior to and post PAM-expansion in uninfected
donors and PLWH on ART. Comparable mean expression of basal (A) CD16 and (B) CD56 on Vδ2
cells between uninfected and PLWH and after seven days of exposure to PAM and IL-2, p = 0.42 and
p = 0.43, respectively, Mann Whitney U-test. Both uninfected and PLWH increased CD16 and CD56
expression upon expansion (p < 0.001 and p < 0.001, respectively, Wilcoxon matched pairs signed rank
test). (C) Similar distribution of basal and expanded mean CD16 expression on Vδ2 cells from nine
African American (A ) and ten sian (CC) PLWH d nors (p = 0.08 and p = 0.60, respectively,
Mann Whitney U-test). Comparable mean basal a ed D56 expression on Vδ2 cells in six AA
and ten CC donors (p = 0.26 and p = 0.84, respectively, Man Whitne -t t).
We n xt an lyzed whether ex i of these markers was different according to race in PLWH
(African American (AA) co pared to Caucasian (CC), since only one individual was Hispanic).
AA donors had a mean of 0.3% Vδ2 cells within total CD3+ lymphocytes compared to CC donors that
had 0.5% (p = 0.89, Mann–Whitney U-test). Race information was not available for the uninfected
group. Data on CD16 expression was available in nine AA and ten CC donors, and CD56 expression
was available in six AA and ten CC donors. Both CD16 and CD56 expression was similarly distributed
in ex vivo and expanded Vδ2 cells. Mean baseline CD16 expression in AA was 8.2% compared to 11.7%
in CC, while mean CD16 expression on expanded Vδ2 cells was 27.1% in AA compared to 33.4% in CC
(Figure 1C, p = 0.42 and p = 0.43, respectively, Mann–Whitney U-test). Mean baseline CD56 expression
was 28.4% in AA ompared to 17.8% in CC, while mean expression on expanded Vδ2 cells was 45.2%
in AA, compared to 43.7% in CC (Figure 1C, p = 0.59 and p = 0.63, respectively, Mann Whitney U-test).
3.3. Similar Composition of Vδ2 Cell Populations in Uninfected Donors and PLWH
Memory and effector Vδ2 cell populations among PBMCs were defined as previously described [19]
γδ(28+) were defined as [CD28+CD27+CD16-], γδ(28−) were [CD28-CD27+CD16-], γδ(16−) expressed
[CD28-CD27-CD16-], and finally γδ(16+) were [CD28-CD27-CD16+]. Baseline Vδ2 cell populations
were comparable between uninfected donors and PL H (Figure 2A). To analyze whether expansion
alters Vδ2 cell phenotype composition, PBMCs from PLWH and uninfected donors were treated
with PAM and IL-2 for seven days. In PLWH the frequency of the γδ(28+) population decreased
while the frequency of the o her three p pulations γδ(28−), γδ(16−), and γδ(16+) increased (Figure 2B),
and the pattern was similar in PLWH treated in acute or chronic phases of the infection (Figure 2C).
Uninfected individuals showed a similar pattern to PLWH except for the γδ(28−) population that
maintained a constant frequency after seven days of expansion (Figure 2D). Incubation with PAM and
IL-2 for 7 days induced a comparable fold-change expansion between PLWH and uninfected donors,
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showing the greatest impact on the CD27-CD28- effector memory populations, and especially in the
cytotoxic CD16+ subpopulation (Figure 2E).
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Figure 2. Vδ2 cell populations in uninfected and PLWH. γδ(28+), γδ(28−), γδ(16+), and γδ(16+)
Vδ2 cell opulations were defined as 27 CD28+CD16- (γδ(28+)); CD27+CD 8-CD16- (γδ(28−));
CD27- 28 CD16- (γδ(16+)) and CD27-CD28-CD16+ (γδ(16+)), and analyzed in ex vivo (Basal) Vδ2 cells
and after 7 days of expans on with PAM and IL-2 (Expa ded) in 23 uninfected donors and 20 PLWH on
ART. (A) Co ara le ex vivo distribution of Vδ2 cell populations i uninfected donors and PLWH
(p = 0.12, p = 0.07, p = 0.54, p = 0.40, respectively, ann hitney U test). (B) Distribution of basal and
expanded Vδ2 cell subpopulations in PLWH. γδ(28+) subpopulation decreased while γδ(28−), γδ(16−),
and γδ(16+) increased after expansion (Wilcoxon paired-signed rank test). (C) Comparable Vδ2 cell
populations between PLWH treated in the acute or chronic phase of HIV infection (p = 0.63, p = 0.61,
p = 0.67 and p = 0.77, respectively, Wilcoxon paired-signed rank test). (D) PAM expansion induced a
decrease in the γδ(28+) population, an increase in γδ(16−) and γδ(16+), while γδ(28−) remained unchanged
(p = 0.27) in uninfected donors (Wilcoxon matched-pairs signed rank test). (E) Fold-change expansion
in uninfected donors and PLWH was comparable for all Vδ2 cell populations (p = 0.15, p = 0.07,
p = 0.76, and p = 0.27, respectively, Mann Whitney U test). Numbers above the symbols in panels (A–D)
represent the mean of each Vδ2 cell population, and in panel (E) represents the mean fold-change
(expanded/basal) in Vδ2 cell populations.
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3.4. Vδ2 Cell Populations Are Distributed amongst Several Profiles in Both Uninfected Donors and PLWH
According to the relative distribution of effector/memory Vδ2 cell populations, healthy individuals
can be classified into six different functional groups or profiles [19]. Each profile is distinguished
by the relative proportions of Vδ2 cell subpopulations (γδ(28+), γδ(28−), γδ(16−), γδ(16+)). Profiles 1–4
are dominated by γδ(28+) and γδ(28−) populations. This is contrasted by profile 5 which has a fairly
equal representation of γδ(16−) and γδ(16+) and profile 6 which has a single dominant population
defined as γδ(16+). Differences in subpopulation frequencies were also shown to be predictive of
functional responses to antigen stimulation. Donors with a pre-existing γδ(28+) immunodominant
profile demonstrated substantial proliferation compared to donors possessing a profile marked by
a higher γδ(16+) population. Instead, the latter were shown to have significantly higher cytotoxic
potential. The distribution of our cohort of 23 uninfected individuals was similar to what has been
previously reported, although less prevalent profiles five and six were lacking. This difference is most
likely due to the smaller sample size of the current study (Figure 3A). Similarly, Vδ2 cell populations
from PLWH were classified into four distinct profiles (Figure 3B). In PLWH, age, sex, initiation of
ART in acute or chronic HIV infection and time on ART (p > 0.05, not shown), did not influence the
distribution of Vδ2 cell populations. Interestingly, although overall expression of CD16 on Vδ2 cells
was similar between AA and CC PLWH donors (Figure 1C), AA donors were most likely grouped in
profile 1 while CC were mostly grouped in profile 2 (Figure 3C, p = 0.02, Fisher exact test), with one
Hispanic individual classified in Profile 3. In addition, CD4 T cell count at the time of the study or
CD4 T cell count nadir were not associated with Vδ2 cell populations’ distribution (Figure 3D, p = 0.95
and p = 0.28, respectively, Kruskal–Wallis rank sum test). CD8 T cell count had a marginal effect and
individuals with higher CD8 T cell frequency of were preferentially grouped in profile 2 (Figure 3D,
p = 0.07, Kruskal–Wallis rank sum test).
3.5. Cytokine Release after Vδ2 Cell Expansion
We analyzed total levels of TH1 cytokines IFN-γ and TNF-α, and GrzB released in the supernatants
of cell cultures after seven days of expansion with PAM and IL-2. In PLWH, levels of IFN-γ were
higher while levels of TNF-α and GrzB were lower compared to uninfected donors (Figure 4A–C).
In addition, in PLWH but not in uninfected donors, GrzB production positively correlated with IFN-γ
release (Figure 4D, p = 0.037). the expression of CD56 on expanded Vδ2 cells positively correlated with
secreted GrzB levels (Figure 4E, p = 0.005). In addition, we analyzed the frequency of NK cells present
in the culture that could be contributing to GrzB production. Although they were present at variable
frequencies, NK cell proportion did not correlate with GrZB production (Supplementary Figure S2,
p = 0.06), suggesting that the majority of this protease was produced by Vδ2 cells. A correlation was
not found between secreted cytokines and GrzB and the total number of Vδ2 cells or CD16 expression
(not shown, p > 0.05 in all cases).
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Figure 4. Cytokine release after seven days of expansion with PAM and IL-2. Quantification of cytokine
levels was performed in supernatants from seven-day expansion cultures. Production of (A) IFN-γ (B)
TNF-α and (C) GrzB in PLWH (N = 12) compared to uninfected donors (N = 7) (Mann-Whitney U-test).
(D) Correlation between GrzB and IFN-γ released in the supernatant of expansion cultures (r = 0.65,
p = 0.037, Spearman’s correlation test). (E) Correlation between GrzB released in the supernatant of
expansion cultures and the frequency of Vδ2 CD56+ cells (r = 0.90, p = 0.005, Spearman’s correlation test).
3.6. Cytolytic Capacity and Vδ2 Cell-Mediated Killing
Vδ2 cells were isolated after ex vivo expansion with PAM and IL-2 and cocultured with Daudi cells
at a 1:1 ratio. Degranulation capacity and intracellular production of perforin and GrzB was measured
in six PLWH and four uninfected individuals (Supplementary Figure S3). Simila express on of CD107a
and production of perforin was fou d betwee both groups (Figure 5A,B). These markers increased
similarly in both PLWH and uninfected individuals upon coculture with Daudi cells (Figure 5A–C).
GrzB production was initially higher in isolated Vδ2 cells from PLWH than in uninfected donors after
expansion (Figure 5C), but production was comparable upon coculture with Daudi cells (Figure 5C).
In addition, since Vδ2 cells from AA PLWH were mostly categorized as central memory cells,
we analyzed whether expanded Vδ2 cells’ cytotoxic function in AA donors was diminished compared
to their CC counterparts. In limited analyses using samples from five individuals, race-dependent
differences in degranulation capacity or intracellular production of perforin or GrzB were not detected
(Figure 5D). CD107a expression positively correlated with both perforin and GrzB production
(Figure 5E,F). Finally, expanded Vδ2 cells from PLWH were able to effectively lyse Daudi cells
(Supplementary Figure S3) in comparable fashion to uninfected donors (Figure 5G). We did not detect
differences in Daudi cell killing according to race in PLWH, although we could only include four
individuals in these analyses (Figure 5H).
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Figure 5. Cytolytic activity on expanded Vδ2 cells. Expanded Vδ2 cells were isolated and cocultured
with Daudi cells (1:1 ratio) and degranulation and functional assays performed in uninfected donors
(n = 4) and PLWH (n = 6). (A) Degranulation capacity was measured analyzing CD107a surface
expression in isolated Vδ2 cells after expansion and upon coculture with Daudi cells. CD107a expression
increased similarly in uninfected donors and PLWH (p = 0.81, Mann Whitney U-test). (B) Expanded
Vδ2 cell intracellular production of perforin increased upon coculture with Daudi cells and was
compar ble betwe n uni f ors and PLWH (p = 0.97 and p = .60, respectively, Mann-Whitney
U-t st). (C) Expanded Vδ2 cells from PLWH produced more t an uninfecte d nors (p = 0.02,
Mann-Whitney U-test). Upon c culture with Daudi cells, similar GrzB pro cti ong uninfected
donors and PLWH was measured (p = 0.34, Mann-Whitney U-test). (D) Degranulation capacity
and production of perforin and GrzB was similar in African American (AA) and Caucasian (CC)
PLWH (p > 0.05, Mann Whitney U-test). Positive correlation between (E) CD107a and perforin
production, and (F) CD107a and GrzB (Spearman correlation test). (G) Vδ2 cell-mediated Daudi
cell killing was comparable between uninfected donors and PLWH (p > 0.05, Mann Whitney U-test).
(H) Comparable Vδ2-cell killing capacity between African American (AA) (n = 4) and Caucasian (CC)
(n = 4) donors among PLWH (p > 0.05, Mann Whitney U-test).
3.7. TCR Repertoire Analysis
Sequencing of TCRγ transcripts from PLWH patients on stable and suppressive ART for >1 year
did not reveal any obvious selection for particular Vγ-regions when compared with uninfected controls
(Figure 6A). Moreover, activation of PBMCs with PAM and IL-2 led to preferential expansion of Vγ9
(that pairs with Vδ2 in phosphoantigen-responsive γδ T cells) sequences in both groups (Figure 6A).
Evaluation of shared Vγ9 sequences within each group and between each group revealed that each
individual shared Vγ9 sequences with at least four other individuals from the total cohort (Figure 6B).
Thus, PLWH retain Vδ2 cells that use “public” Vγ9 sequences that have previously been identified as
being present in multiple individuals in the general population.
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Figure 6. TCRγ chain analysis in uninfected donors compared to PLWH. (A) TCRγ chain usage ex vivo
(black) and after expansion (grey). (B) Publicity of Vγ9 sequences, showing the number f shared CDR3
Vγ9 sequences shared between the 8 individuals of the cohort. (C) ( eft) Tree maps showing Vγ9 CDR3
clonotypes relative to repertoire size for uninfected and PLWH samples ex vivo with graphs below
showing percentage clone abundance (grey bars) (left y-axis) for the top 10 most prevalent clonotypes.
Accumulated frequency of the top 10 clonotypes is shown on the same graph (black line above bars).
(Right) Graphs show the percentage of Vγ9 CDR3 clonotypes that make up various proportions of the
total repertoire i.e., D25 (25%), D50 (50%), and D75 (75%). (D) Tree maps of uninfected and PLWH
samples after 7-day treatment with PAM + IL-2. Representative PLWH samples are shown based on
lowest and highest number of clonotypes. (E) Vγ9 CDR3 length from ex vivo and expanded samples
from uninfected donors (UC) and PLWH. Ex vivo: UC (n = 2), PLWH (n = 4). Expanded: UC (n = 4),
PLWH (n = 4).
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Analysis of Vγ9 sequences in ex vivo PBMCs revealed that PLWH may possess reduced repertoire
diversity compared to uninfected donors as measured by TCR occupancy (Figure 6C). Although our
limited sample size of uninfected donors limits making definitive conclusions from this stage of the
analysis. In contrast, PBMCs treated with PAM and IL-2 showed broadly similar patterns in all eight
individuals, with no evidence of skewness towards either restricted or diverse repertoires in PLWH,
suggesting expansion of a similar range of Vγ9 clones (Figure 6D).
Finally, analysis of Vγ9 CDR3 nucleotide length showed that samples from ex vivo PLWH samples
had shorter CDR3s when compared with samples from uninfected donors, although no particular
CDR3 length size was selected (Figure 6E). Interestingly, after PAM and IL-2 exposure, the pattern of
CDR3 length was similar for samples from uninfected donors and PLWH, with preferential expansion
of CDR3s with nucleotide length of 48 and to a lesser extent lengths 46, 52, and, 54 (Figure 6E).
4. Discussion
Vδ2 cells are key contributors to immune crosstalk that drives the TH1 cell-mediated responses
needed for clearance of microbial infections [28]. HIV infection specifically causes the depletion and
dysregulation of circulating Vδ2 cells [25,27,29]. It is clear that treatment is unable to reconstitute the
overall number of Vδ2 cells, but determining the capacity of ART to restore their functionality is a
contentious subject [30]. In this study, we have compared the phenotype, cytotoxic capacity, and TCR
repertoire of Vδ2 cells from uninfected donors and PLWH on suppressive ART for >1 year. Although
numerically reduced, Vδ2 cells from PLWH and uninfected donors had comparable: (1) ex vivo
frequencies of proliferative and cytotoxic Vδ2 cell subpopulations, (2) clonal responses to PAM + IL-2
(3) degranulation and cytotoxic function. Our results indicate that despite sustained depletion in
treated infection, PLWH on continuous and suppressive ART possess comparable Vδ2 cell phenotypes
and functionality than uninfected individuals.
HIV-mediated depletion of Vδ2 cells preferentially affects those expressing a Vγ9-Jγ1.2 TCR
leaving behind a repertoire that shows attenuated responsiveness to P-Ag stimulation [23,31,32]. This is
evident in the diminished in vitro expansion following P-Ag stimulation, as previously reported by
our group and others [22,33]. In contrast, Vδ2 cells in PLWH retain the ability to expand in the presence
of N-BPs, such as PAM and ZOL, similar to uninfected donors [34,35]. Our results show that PLWH
may possess less diverse Vδ2 cell TCR repertoires compared to uninfected donors ex vivo, but similar
induced clonality as a result of expansion with PAM + IL-2 was observed. The presence of antigen
driven activation raises the possibility that ART may recover some Vδ2 cell functionality in fully
suppressed individuals, although a longitudinal study in PLWH is required to confirm this finding.
We (P.L.R and D.J.P) previously characterized Vδ2 T cell composition in healthy individuals
showing a heterogeneous distribution of CD27, CD28 and CD16 expression, and defined distinct
proliferative and cytotoxic phenotypic profiles based on these distributions [19]. In this study,
we analyzed Vδ2 cell phenotype and found that levels of CD16 and CD56 on Vδ2 cells were
comparable between uninfected donors and PLWH. CD16+ Vδ2 cell populations are associated
with poor proliferative responses, control of HIV infection, and elimination of latently HIV-infected
cells [13,14,22]. Using previously defined Vδ2 cell phenotype classification [19], our results show a
similar composition and distribution of Vδ2 cell population profiles in uninfected donors and PLWH.
After one week of ex vivo stimulation with PAM and IL-2, the frequency of γδ(28+) cells from PLWH
decreased while the γδ(28−), γδ(16−) and γδ(16+) populations increased. These results demonstrate that
Vδ2 cell profile distribution and ability to upregulate cytotoxic markers is not impaired in PLWH on
extended suppressive ART.
Several factors such as age, sex, and ethnicity, may impact Vδ2 cell profile distribution [18,36,37].
It has been previously reported that AA-uninfected individuals harbor a lower frequency of Vδ2 cells
expressing CD56 and a higher frequency of cells primarily grouped within profile number 1 [17].
This profile is defined by a central memory phenotype associated with more proliferative and less
cytotoxic responses [19]. Accordingly, we found that Vδ2 cells from AA PLWH grouped primarily in
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profile number 1. This observation may have critical therapeutic implications that warrant further
investigation. An absence of information on the races of uninfected donors prevented extending our
analysis to this cohort. Lastly, it has also been suggested that recovery of Vδ2 functionality is dependent
upon the level of αβCD4 T cells [38]. We did not find a significant impact of CD4 counts on Vδ2 cell
phenotypes, but we did detect a marginal effect associated with the frequency of total CD8 T cells.
In addition to depletion, HIV infection results in severe impairment of Vδ2 cell cytokine production
and cytolytic capabilities [32,39]. This dysregulation is marked by a decrease in the secretion of
proinflammatory cytokines IFN-γ and TNF-α as well as reduced killing capacity of Daudi cells.
Previous studies on donors with variable viral suppression and time on ART have shown that
prolonged ART may not completely restore these functions [40,41]. To our knowledge, our current
study is the first to utilize a cohort of donors with complete viral suppression and a treatment duration
of >1 year at the time of enrollment. We found that Vδ2 cells from PLWH are capable of cytokine
production and display comparable killing capacity to uninfected donors. These results are in line with
our previous work showing that PAM-expanded Vδ2 cells from ART-suppressed PLWH are capable of
inhibiting viral replication and eliminating latently HIV-infected cells [22]. Although our measurement
of cytokine production came from cultures with mixed PBMC populations [24], a positive correlation
with CD56+ Vδ2 cells indicate they may represent the most abundant cytokine-producing population.
Taken together, these data indicate that sustained ART is able to restore cytotoxic function of activated
Vδ2 cell populations.
Although we have established that Vδ2 cell cytotoxic function is comparable between uninfected
donors and PLWH who are fully suppressed for more than one year, there are some features that
remain altered. In addition to low total circulating numbers, our results show lower TNF-α production
along with higher IFN-γ and GrzB, most likely associated to HIV exposure. One possible explanation
could be Vδ2 cells’ role as a reservoir for HIV [25]. While active HIV infection of γδ T cells does
not appear to have a drastic impact on cytokine related function, it is unclear if integrated provirus
alters their polyfunctionality [32]. Nevertheless, our observation of increased GrzB+ Vδ2 cells and
higher IFN-γ upon ex vivo expansion fits with previous studies that suggest γδ T cells play a part
in driving systemic inflammation that leads to HIV-associated comorbidities such as cardiovascular
disease [42]. Alternatively, the combined increase in degranulation markers and IFN-γ may be
indicative of some degree of HIV-specific Vδ2 cell responses that necessitate further investigation [22].
These findings add crucial information to the evaluation of ART and may guide the development of
γδT cell immunotherapies aimed at curing persistent HIV infection
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